Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + Trastuzumab + AI in HR+/HER2+ Breast Cancer
NCT05885776Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2022
- Primary completion
- Mar 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Pathological Complete Response Rate (ypT0-is/ypN0) at 18 weeks. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05885776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885776.